Dr. Zvonko Milicevic presented the potential antifibrotic effects of triple agonist GLP-1/GIP/glucagon (retratrutide) in a subgroup of a diabetes trial focused on MAFLD. This evidence concerns the gene GCG and diabetes mellitus.